🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

For all who continue to doubt Hamas’ use of hospitals as shields for their barbarism.

Grateful for the opportunity to serve the ASTRO community! Looking forward to promoting the outstanding scholarship and advances in our field! ASTRO #AdvancesRO

Results of B51 show patient selection for RNI based on response to systemic therapy is safe at first report! #SABCS23 Subtypes represented. Over half got SLN. Longer follow up planned; EBCTCG question: study notes RNI benefit is a long term investment. #radonc

I hope all of those who have publicly downplayed this barbarism or have fallen silent in the face of it will read this piece and share it: nytimes.com/2023/12/28/wor…

More than 250 Jewish students at Columbia have signed this open letter. If you have 5 minutes today, take the time to read it. Because the sentiments it expresses are what the overwhelming majority of Jewish people feel. docs.google.com/document/u/1/d…

NEW: Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT #lymphoma: a single-centre, pilot trial MD Anderson Cancer Center #lymsm thelancet.com/journals/lanha…

New in #practicalRO: Radiation Pneumonitis after Partial Breast Irradiation. #radonc bit.ly/probrooks1

They were just children playing soccer. No words.

RT-CHARM results. IMO, moderate HF is now standard of care for T1-3 N1 breast cancer, with or without reconstruction.

Current thoughts on PBI. nam02.safelinks.protection.outlook.com/?url=https%3A%…

SABCS24 - EUROPA Trial. Sig improved QOL at 2y with RT (1-3 week WBI or PBI) compared to ET. Fewer treatment related events associated with RT. No recurrences in either arm.

SABCS24-Dr. Wright, Analysis of Tam on pts treated with Lump alone on E5914 and RTOG 9804. Recurrence nearly halved (HR 0.52) with Tam for good risk DCIS.

SABCS24-SUPREMO Trial, 10y results, +/- PMRT for T1-2N1, T3N0, or T2N0 if LVI or G3. Needed 8+ LNs removed. OS not improved, sig less LF (2.5% v 1.1%) with PMRT, But very low. Does this help s/p SLNbx for N+?

SABCS24-INSEMA Trial. Rand +/- SLNBx for cT1-2N0 all ax U/S, lump/RT to breast only. N=5502. No diff in invDFS or OS. Very low LRF. Together with SOUND trial, appropriate to omit SLNBx for cT1N0 HR+ age >50

SABCS24-EBCTCG Impact of obesity on distant recurrence in 208,904 pts. Obesity worsens DM; impact worsens linearly with increased BMI. Impact greater for PREmenopausal. Effect same for HR+ and HR-

Response-adapted 4 Gy ▶️ 20-24 Gy in potentially curable iNHL. 281 pts, only 6% addn'l RT. 5-yr local progression 15%, 5-yr distant PD 22%. Randomized trial forthcoming. We have been doing this at CU Lymphoma Program (with Rachel Rabinovitch & Sarah Milgrom, MD) with success. #lymsm #18ICML